Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils

Our findings identify GPR34 as a promising therapeutic target for enhancing microglial Aβ clearance and highlight the potential of GPR34 agonists for AD treatment. The age-dependent decline in GPR34 expression may contribute to reduced Aβ clearance efficiency in aging brains, exacerbating amyloid accumulation. Pharmacological activation of GPR34 represents a novel strategy to counteract impaired Aβ clearance in both aging and AD brains, potentially modifying disease progression through enhancement of microglial phagocytic function.

Authors

Institutions

Publication Details

Journal
Alzheimer s Research & Therapy
Published
2025-11-20
DOI
https://doi.org/10.1186/s13195-025-01891-8
Citations
3
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
3.49

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils

Norikazu Hara, Tomohiko Ohwada, Takaomi C. Saido, Shigeo Murayama et al.
3 citations
Alzheimer s Research & Therapy
Alzheimer's disease research and treatments
3.49
article

Selective agonism of GPR34 stimulates microglial uptake and clearance of amyloid β fibrils

Norikazu Hara, Tomohiko Ohwada, Takaomi C. Saido, Shigeo Murayama, Junken Aoki, Sho Takatori, Hideyuki Okano, Iki Sonn, Takeshi Ikeuchi, M. Hasegawa, Maho Morishima, Takashi Saito, Toshiyuki Takai, Jumpei Omi, Hayato Etani, Masataka Kikuchi, Yusuke Amiya, Taisuke Tomita, Akinori Miyashita, Aika Akahori, Wenbo Wang, H Watanabe, Yuko Saito
article en
3 citations

Abstract

Our findings identify GPR34 as a promising therapeutic target for enhancing microglial Aβ clearance and highlight the potential of GPR34 agonists for AD treatment. The age-dependent decline in GPR34 expression may contribute to reduced Aβ clearance efficiency in aging brains, exacerbating amyloid accumulation. Pharmacological activation of GPR34 represents a novel strategy to counteract impaired Aβ clearance in both aging and AD brains, potentially modifying disease progression through enhancement of microglial phagocytic function.

Alzheimer s Research & TherapyVol. 17(1)
Tohoku University (JP), Keio University (JP), RIKEN Center for Brain Science (JP), Nagoya City University (JP), Tokyo Metropolitan Institute of Gerontology (JP), Niigata University (JP), The University of Tokyo (JP)
Japan Society for the Promotion of Science
Openalex Percentile: Top 7%
Alzheimer's disease research and treatments
3.49
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.